F C Schell - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

F C Schell

Showing results (1-10 of 10) with videos related to

Pageof 1

Sort By:

Cancer Treatment Reports|August 1, 1982

Potential cardiotoxicity with mitoxantroneF C Schell, H Y Yap, G Blumenschein, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1982

Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinomaF C Schell, H Y Yap, G N Hortobagyi, et al.

American Journal of Clinical Oncology|February 1, 1983

Phase II clinical evaluation of AZQ in metastatic breast cancerH Y Yap, A Y Bedikian, F C Schell, et al.

Annals of Internal Medicine|December 1, 1981

Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancerH Y Yap, G R Blumenschein, F C Schell, et al.

American Journal of Clinical Oncology|October 1, 1982

Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancerH Y Yap, G R Blumenschein, G N Hortobagyi, et al.

Cancer Research|March 1, 1983

Bisantrene, an active new drug in the treatment of metastatic breast cancerH Y Yap, B S Yap, G R Blumenschein, et al.

Journal of Surgical Oncology|January 1, 1981

Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapyG N Hortobagyi, G R Blumenschein, A U Buzdar, et al.

Cancer|May 1, 1982

Peptichemio versus melphalan (L-PAM) in advanced breast cancerA U Buzdar, S S Legha, G R Blumenschein, et al.

Cancer|June 15, 1981

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimensA U Buzdar, S S Legha, G N Hortobagyi, et al.

Cancer|February 1, 1984

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trialA U Buzdar, G R Blumenschein, T L Smith, et al.

Pageof 1

Search research articles

Showing results (1-10 of 10) with videos related to

Sort By:

Pageof 1

Cancer Treatment Reports|August 1, 1982

Potential cardiotoxicity with mitoxantroneF C Schell, H Y Yap, G Blumenschein, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1982

Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinomaF C Schell, H Y Yap, G N Hortobagyi, et al.

American Journal of Clinical Oncology|February 1, 1983

Phase II clinical evaluation of AZQ in metastatic breast cancerH Y Yap, A Y Bedikian, F C Schell, et al.

Annals of Internal Medicine|December 1, 1981

Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancerH Y Yap, G R Blumenschein, F C Schell, et al.

American Journal of Clinical Oncology|October 1, 1982

Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancerH Y Yap, G R Blumenschein, G N Hortobagyi, et al.

Cancer Research|March 1, 1983

Bisantrene, an active new drug in the treatment of metastatic breast cancerH Y Yap, B S Yap, G R Blumenschein, et al.

Journal of Surgical Oncology|January 1, 1981

Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapyG N Hortobagyi, G R Blumenschein, A U Buzdar, et al.

Cancer|May 1, 1982

Peptichemio versus melphalan (L-PAM) in advanced breast cancerA U Buzdar, S S Legha, G R Blumenschein, et al.

Cancer|June 15, 1981

Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimensA U Buzdar, S S Legha, G N Hortobagyi, et al.

Cancer|February 1, 1984

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trialA U Buzdar, G R Blumenschein, T L Smith, et al.

Pageof 1